Why small-molecule development risk is often discovered too late Small-molecule development does not usually fail because teams lack effort. It fails because risk is discovered too late. The cost then appears as rework, delayed approvals, or supply plans that collapse […]
In small-molecule development, risk rarely appears as a single obvious event. It usually emerges through an atypical analytical result that cannot be defended, a stability trend that forces reformulation, a tech transfer that loses process intent, or an HPAPI handling gap that […]
Optimizing fill–finish for biologics begins at a point where resources are constrained, knowledge is incomplete, and regulatory scrutiny is intense. The central task is to convert a promising molecule into a phase-appropriate, manufacturable dosage form that is safe, stable, and clinically usable—often […]
In the high-stakes world of small-molecule development, the transition from pre-clinical “garage-style” synthesis to a scalable, GMP-ready clinical candidate is where most asset valuations either soar or plummet. For small and mid-sized pharma companies, this is not just a technical hurdle, it is a […]
In the highly regulated world of pharmaceutical manufacturing, the production of controlled substances represents a pinnacle of complexity. The process demands that requirements for quality, safety, operability, regulatory compliance, and security are all satisfied simultaneously. This unyielding standard necessitates an […]
In the high-stakes world of aseptic manufacturing, the distance between a successful batch and a multi-million-euro “atypical finding” is often measured in millimeters—the diameter of a tubing line, the viscosity of a bulk solution, or the precise pressure of a […]
Get notified on our latest news.
